BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 18086798)

  • 21. Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Watanabe R; Tomita N; Kishimoto K; Koyama S; Ogusa E; Ishii Y; Miyashita K; Matsuura S; Fujisawa S; Hattori Y; Takasaki H; Fujita A; Ohshima R; Kuwabara H; Hashimoto C; Fujimaki K; Sakai R; Ishigatsubo Y
    Leuk Res; 2013 Oct; 37(10):1208-12. PubMed ID: 23927994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98.
    Martinelli G; Schmitz SF; Utiger U; Cerny T; Hess U; Bassi S; Okkinga E; Stupp R; Stahel R; Heizmann M; Vorobiof D; Lohri A; Dietrich PY; Zucca E; Ghielmini M
    J Clin Oncol; 2010 Oct; 28(29):4480-4. PubMed ID: 20697092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
    Coiffier B; Neidhardt-Bérard EM; Tilly H; Belanger C; Bouabdallah R; Haioun C; Brice P; Péaud PY; Pico JL; Janvier M; Solal-Celigny P; Brousse N
    Ann Oncol; 1999 Oct; 10(10):1191-7. PubMed ID: 10586336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
    Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
    Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
    Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
    J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association.
    Kridel R; Xerri L; Gelas-Dore B; Tan K; Feugier P; Vawda A; Canioni D; Farinha P; Boussetta S; Moccia AA; Brice P; Chavez EA; Kyle AH; Scott DW; Sanders AD; Fabiani B; Slack GW; Minchinton AI; Haioun C; Connors JM; Sehn LH; Steidl C; Gascoyne RD; Salles G
    Clin Cancer Res; 2015 Aug; 21(15):3428-35. PubMed ID: 25869385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma.
    Richendollar BG; Pohlman B; Elson P; Hsi ED
    Hum Pathol; 2011 Apr; 42(4):552-7. PubMed ID: 21237493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
    Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
    Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Achieving Bcl-2/IgH negativity in peripheral blood/bone marrow after therapy implies better prognosis for patients with follicular lymphoma].
    Belada D; Smolej L; Stepánková P; Beránek M; Dvoráková D; Bukac J; Malý J
    Vnitr Lek; 2007 Oct; 53(10):1057-63. PubMed ID: 18072430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
    Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
    Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group.
    Klapper W; Hoster E; Rölver L; Schrader C; Janssen D; Tiemann M; Bernd HW; Determann O; Hansmann ML; Möller P; Feller A; Stein H; Wacker HH; Dreyling M; Unterhalt M; Hiddemann W; Ott G;
    J Clin Oncol; 2007 Aug; 25(22):3330-6. PubMed ID: 17664481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
    Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
    J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
    Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
    Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
    Nagai H; Yano T; Watanabe T; Uike N; Okamura S; Hanada S; Kawano F; Sunami K; Inoue N; Sawamura M; Nishiura T; Hotta T; Horibe K
    Br J Haematol; 2008 Dec; 143(5):672-80. PubMed ID: 18950459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
    Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
    Mishima Y; Sugimura N; Matsumoto-Mishima Y; Terui Y; Takeuchi K; Asai S; Ennishi D; Asai H; Yokoyama M; Kojima K; Hatake K
    Clin Cancer Res; 2009 May; 15(10):3624-32. PubMed ID: 19417028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
    Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
    Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: an aid to clinical decision making.
    Cole BF; Solal-Céligny P; Gelber RD; Lepage E; Gisselbrecht C; Reyes F; Sebban C; Sugano D; Tendler C; Goldhirsch A
    J Clin Oncol; 1998 Jul; 16(7):2339-44. PubMed ID: 9667248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
    Jäger G; Quehenberger F; Linkesch W; Neumeister P
    Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.